Clinical trials: Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme, Glioma
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
Objectives: 1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or progressive malignant gliomas.
- Trial name
- NCT00412542
- Testing
- Thalidomide, CPT-11, MRI Scan
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Memantine for Recurrent Glioblastoma
The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth…
- Trial name
- NCT01260467
- Testing
- memantine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Rochester
Recurrent Glioblastoma, Recurrent Gliosarcoma
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma
- Trial name
- NCT04477200
- Testing
- Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
The purpose of this study is to investigate the safety and performance of an investigational agent, known as 5-ALA or Gliolan (aminolevulinic acid), that many be useful to a surgeon for visualizing a tumor during surgery.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01575275
- Testing
- aminolevulinic acid, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Michael Vogelbaum, MD, PhD
Recurrent Glioblastoma
Mathematical Model-Adapted Radiation In Glioblastoma
This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma.
- Trial name
- NCT03557372
- Testing
- Mathematical Model-Adapted Radiation Fractionation Schedule
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Glioblastoma
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.
- Trial name
- NCT04013672
- Testing
- Pembrolizumab, SurVaxM, Sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- David Peereboom
Glioblastoma, Gliosarcoma
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate…
- Trial name
- NCT00613028
- Testing
- Temo + Avastin, VP-16 + Avastin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Cancer of Brain and Nervous System
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
All patients will complete best standard of care radiation, temozolomide and bevacizumab (6 weeks). Within two weeks of completion of this initial treatment period, study patients will be fitted with the NovoTTF-100A System and…
- Trial name
- NCT02343549
- Testing
- NovoTTF100A, Bevacizumab, Temozolomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Wake Forest University Health Sciences
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone…
- Trial name
- ACTIVATe (NCT00643097)
- Testing
- PEP-3 vaccine, sargramostim, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- John Sampson
Glioblastoma Multiforme
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine.
- Trial name
- NCT00323115
- Testing
- Autologous Dendritic Cell, Temozolomide, Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Glioblastoma Multiforme, Anaplastic Oligoastrocytoma
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT02026271
- Testing
- Ad-RTS-hIL-12, veledimex
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma
Tivozanib for Recurrent Glioblastoma
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01846871
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma Multiforme, Glioblastoma
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
- Trial name
- NCT02663271
- Testing
- Bevacizumab, Optune, Brain MRI
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Advanced Malignant Solid Neoplasm, Glioblastoma
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in…
- Conditions
- Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma
- Trial name
- NCT03212274
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 51 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Glioblastoma Multiforme
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
There will be 2 phases in this study. Patients will either be enrolled to the first phase or to the second phase, depending upon when they enroll into the study.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
- Trial name
- NCT00402116
- Testing
- enzastaurin, temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company